GTS Securities’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-20,600
Closed -$70.2K 2070
2024
Q3
$70.2K Sell
20,600
-5,500
-21% -$23.9K ﹤0.01% 3851
2024
Q2
$122K Sell
26,100
-14,300
-35% -$80.7K ﹤0.01% 3580
2024
Q1
$300K Buy
40,400
+12,700
+46% +$106K ﹤0.01% 2988
2023
Q4
$281K Buy
27,700
+3,400
+14% +$29.8K ﹤0.01% 3271
2023
Q3
$190K Buy
+24,300
New +$208K ﹤0.01% 3433

Other funds holding EDIT

GTS Securities's EDIT Position: Q4 2024 in Review

GTS Securities sold out of Editas Medicine (EDIT) in Q4 2024, closing a stake of 11,151 shares — an estimated $38K sold.

GTS Securities first reported a position in EDIT in Q2 2023 and held it in 6 quarters. The position peaked at $517K in Q4 2023. 206 funds tracked by Wall St. Rank hold EDIT as of Q4 2024.

  • GTS Securities reported no remaining Editas Medicine position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 11,151 Editas Medicine shares in Q4 2024, an estimated $38K.
  • GTS Securities first reported a position in Editas Medicine in Q2 2023 and held it in 6 quarters.
  • GTS Securities's Editas Medicine position peaked at $517K in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.